Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia

Journal of Clinical Pharmacy and Therapeutics

Volumn 34, Issue 5, 2009, Pages 607-610

  Al Kali, A ^a,b   Farooq, S ^a   Tfayli, A ^a  

^a OKLAHOMA CITY UNIVERSITY   (United States)

^b 920 Stanton Young Blvd WP 2040 ^*  (United States)

Author keywords

Drug related; Tumour lysis syndrome

Indexed keywords

BRONCHODILATING AGENT; CILASTATIN PLUS IMIPENEM; HYDROXYUREA; IMATINIB; RASBURICASE;

ACUTE KIDNEY FAILURE; AGED; ALKALINIZATION; ANEMIA; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CONSCIOUSNESS; DIARRHEA; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE CONCENTRATE; FEMALE; FLUID THERAPY; FOOT EDEMA; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; MENTAL INSTABILITY; NAUSEA AND VOMITING; PNEUMONIA; POSITIVE END EXPIRATORY PRESSURE; SIDE EFFECT; SPLENOMEGALY; TUMOR LYSIS SYNDROME;

AGED; ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY FAILURE, ACUTE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TUMOR LYSIS SYNDROME;

EID: 70049091957     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01035.x     Document Type: Article

References (6)

1. Druker BJ, Sawyers CL, Kantarjian H et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine, 344, 1038 1042.
2. Dann EJ, Fineman R, Rowe JM (2002) Tumor lysis syndrome after STI 571 in Philadelphia chromosome-positive acute lymphoblastic leukemia. Journal of Clinical Oncology, 20, 354 355.
3. Vora A, Bhutani M, Sharma A, Raina V (2002) Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase. Annals of Oncology, 13, 1833 1834.
4. Ali R, Ozkalemkas F, Ozkan A et al. (2007) Tumor lysis syndrome with acute renal failure during imatinib therapy. Leukemia Research, 31, 573 574.
5. Kitiyakara C, Atichartakarn V (2002) Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrology, Dialysis, Transplantation, 17, 685 687.
6. Pou M, Saval N, Vera M, Saurina A, Sole M, Cevantes F, Botey A (2003) Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leukaemia & Lymphoma, 44, 1239 1241.